» Articles » PMID: 36291843

Patterns of Care and Data Quality in a National Registry of Black and White Patients with Merkel Cell Carcinoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Oct 27
PMID 36291843
Authors
Affiliations
Soon will be listed here.
Abstract

Merkel Cell Carcinoma (MCC) is a rare cancer most commonly affecting White patients; less is known for Black patients. We aim to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. We conducted a retrospective cohort analysis between 2006−2017 via the National Cancer Database of Black and White MCC patients with and without known staging information. Multivariable logistic, proportional odds logistic, and baseline category logistic regression models were used for our primary endpoint. Multivariable Cox regression was used to interrogate overall survival. Multiple imputation was used to mitigate missing data bias. 34,503 patients with MCC were included (2566 Black patients). Black patients were younger (median age 52 vs. 72, p < 0.0001), had higher rates of immunosuppression (28% vs. 14%, p = 0.0062), and were more likely to be diagnosed at a higher stage (proportional OR = 1.41, 95% CI 1.25−1.59). No differences were noted by race across receipt of definitive resection (DR), though Black patients did have longer time from diagnosis to DR. Black patients were less likely to receive adjuvant radiation. Black patients were more likely to have missing cancer stage (OR = 1.69, CI 1.52−1.88). Black patients had decreased adjusted risk of mortality (HR 0.73, 0.65−0.81). Given the importance of registry analyses for rare cancers, efforts are needed to ensure complete data coding. Paramount to ensuring equitable access to optimal care for all is the recognition that MCC can occur in Black patients.

Citing Articles

Merkel cell carcinoma among non-Caucasian patients: A retrospective case-control study.

Moy A, Zhou D, Chen J, White C, Riedel E, Pulitzer M J Am Acad Dermatol. 2024; 91(2):362-364.

PMID: 38663746 PMC: 11260525. DOI: 10.1016/j.jaad.2024.04.028.

References
1.
Yin X, She H, Martin Kasyanju Carrero L, Ma W, Zhou B . Nomogram prediction for the overall survival and cancer-specific survival of patients diagnosed with Merkel cell carcinoma. Ann Transl Med. 2021; 9(4):286. PMC: 7944317. DOI: 10.21037/atm-20-4578. View

2.
Aldrighetti C, Niemierko A, Van Allen E, Willers H, Kamran S . Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open. 2021; 4(11):e2133205. PMC: 8576580. DOI: 10.1001/jamanetworkopen.2021.33205. View

3.
Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A . Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021; 13(22). PMC: 8616211. DOI: 10.3390/cancers13225770. View

4.
Vyas D, Eisenstein L, Jones D . Hidden in Plain Sight - Reconsidering the Use of Race Correction in Clinical Algorithms. N Engl J Med. 2020; 383(9):874-882. DOI: 10.1056/NEJMms2004740. View

5.
von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014; 12(12):1495-9. DOI: 10.1016/j.ijsu.2014.07.013. View